Zacks Investment Research·Jun 22, 2026
Here's Why You Should Add LXRX Stock to Your Portfolio NowLexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
Lexicon Pharmaceuticals, Inc.(LXRX)Earnings, Financials & Key Ratios
LXRX•NASDAQ
$2.32
Price updated Jul 6, 2026
AboutLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.Show more
- Revenue$50M+60.2%
- EBITDA-$48M+75.4%
- Net Income-$50M+74.9%
- EPS (Diluted)-0.14+77.8%
- Gross Margin99.45%+1.5%
- EBITDA Margin-96.96%+84.7%
- Operating Margin-98.21%+84.5%
- Net Margin-101.08%+84.3%
- ROE-39.72%+76.3%
LXRX Price & Volume
Lexicon Pharmaceuticals, Inc. (LXRX) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Commercial Launch Trajectory
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity shortfall risk
Key Thesis Takeaways
- Lexicon Pharmaceuticals faces a precarious fundamental outlook as its transition to a commercial-stage entity remains hampered by inconsistent revenue growth and structural operating losses.
- While the company maintains high gross margins exceeding 99%, these are insufficient to offset the heavy R&D and SG&A expenditures required for the INPEFA launch.
- Investors should remain cautious regarding the company's limited $38.1M cash position, which suggests a high probability of future dilutive financing to sustain ongoing operations.
Verdict Logic
the company's precarious liquidity, evidenced by a cash balance of only $38.1M against persistent quarterly operating losses, suggests significant risk of further shareholder dilution.
LXRX Growth Metrics
Lexicon Pharmaceuticals, Inc. (LXRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-9.15%
5 Years15.72%
3 Years610.25%
TTM123.12%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM85.28%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM85.98%
Return on Capital
10 Years-42.34%
5 Years-67.7%
3 Years-67.98%
Last Year-23.44%
LXRX Recent Earnings
Lexicon Pharmaceuticals, Inc. (LXRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.00+93.5%
$0.04
Rev
$21M+115.6%
$10M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
$5M+74.8%
$3M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.04+42.9%
$0.07
Rev
$14M+351.4%
$3M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.01+112.5%
$0.08
Rev
$29M+396.7%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.00vs $0.04+93.5% | $21Mvs $10M+115.6% |
| Q2 2026 | Mar 5, 2026 | $0.04vs $0.07+42.9% | $5Mvs $3M+74.8% |
| Q4 2025 | Nov 6, 2025 | $0.04vs $0.07+42.9% | $14Mvs $3M+351.4% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.08+112.5% | $29Mvs $6M+396.7% |
Based on last 12 quarters of dataView full earnings history →
Latest LXRX News
Recent stock market news and headlines for Lexicon Pharmaceuticals, Inc. (LXRX)
Peers Comparison
Key metrics vs top competitors for Lexicon Pharmaceuticals, Inc. (LXRX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.32 | $1.03B | -16.57 | 60.24% | -101.08% | -39.72% | — | |
| $5.34 | $1.31B | -20.54 | 22.09% | -13.58% | -38.11% | — | |
| $91.61 | $9.83B | 111.72 | 12.79% | 6.23% | 7.5% | — | |
| $21.82 | $1.61B | 6.61 | 18.52% | 118.91% | 47.59% | — | |
| $131.50 | $8.46B | -64.15 | -89.41% | -648.27% | -17.76% | — | |
| $25.77 | $4.41B | 11.25 | 11.87% | 34.3% | 35.65% | — |
Compare LXRX vs Peers
Lexicon Pharmaceuticals, Inc. (LXRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LXRX SEC Filings & Documents
Lexicon Pharmaceuticals, Inc. (LXRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 6, 2026·SEC
Material company update
Apr 30, 2026·SEC
10-K Annual Reports
310-Q Quarterly Reports
6Get notified when LXRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LXRX Frequently Asked Questions
Lexicon Pharmaceuticals, Inc. (LXRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Lexicon Pharmaceuticals, Inc.'s revenue?
Lexicon Pharmaceuticals, Inc. (LXRX) reported $69.6M in revenue for fiscal year 2025. This represents a 1382% increase from $4.7M in 1999.
How fast is Lexicon Pharmaceuticals, Inc. growing?
Lexicon Pharmaceuticals, Inc. (LXRX) grew revenue by 60.2% over the past year. This is strong growth.
Is LXRX profitable?
Lexicon Pharmaceuticals, Inc. (LXRX) reported a net loss of $26.1M for fiscal year 2025.
Dividend & Returns
What is LXRX's return on equity?
Lexicon Pharmaceuticals, Inc. (LXRX) has a return on equity (ROE) of -39.7%. Negative ROE indicates the company is unprofitable.
What is Lexicon Pharmaceuticals, Inc.'s free cash flow?
Lexicon Pharmaceuticals, Inc. (LXRX) had negative free cash flow of $38.8M in fiscal year 2025, likely due to heavy capital investments.